Sinocelltech Group Ltd. (688520)

Overview

Sinocelltech Group Limited is a pioneering biotech enterprise headquartered in Beijing, China. Founded in 2007, it specializes in the exploration and commercialization of recombinant proteins, monoclonal antibodies, and vaccines. Operating primarily within the Chinese market, Sinocelltech has established itself as a leader in the biotechnological industry, committed to addressing complex health challenges. It functions under the umbrella of Lhasa Alike Investment Consulting Co., Ltd, as a key subsidiary. The company's dedication to innovation in biotechnology signifies its vital role in advancing medical treatments and therapies for various diseases, including rare conditions, tumors, and infectious diseases.

Products and Services

• AnpingxiA (repertuzumab injection) - This groundbreaking anti-tumor product showcases Sinocelltech’s prowess in oncology, offering new hope for cancer patients.
• Anjiayin - Targeted at treating hemophilia A, Anjiayin represents a critical advancement towards managing this rare bleeding disorder, providing patients with an effective therapy option.
• Coronavirus 2-valent (trimer protein vaccine) - Designed to combat the coronavirus, this trimer protein vaccine underscores Sinocelltech's response to global pandemic challenges with innovative immunization solutions.
• Mutant strain recombinant protein vaccines SCTV01C and SCTV01E - These vaccines further Sinocelltech's commitment to fighting infectious diseases by addressing evolving pathogens with cutting-edge research and development.
• SCT630 - Focused on autoimmune diseases, SCT630 is being developed to offer relief to patients suffering from chronic conditions that impact their quality of life significantly.
• SCT510 (For the treatment of solid tumors) - This represents another facet of Sinocelltech’s extensive research in oncology, aiming to provide novel treatment options for various solid tumors.
• SCT-I10A (Monoclonal antibody injection) - Currently in phase 3 trials for solid tumors, this monoclonal antibody injection exemplifies the company’s innovative approach in targeting cancer.
• SCTV01 (New generation vaccine) - In phase 3 trials for the treatment of coronavirus, SCTV01 showcases Sinocelltech’s relentless pursuit of breakthrough vaccines in response to infectious disease threats.
• SCT200 (Monoclonal antibody injection) - Another key player in the arsenal against solid tumors, reinforcing Sinocelltech’s commitment to broadening the horizons in cancer treatment.
• SCT1000 (Human papillomavirus treatment) - Currently in phase 3 clinical trials, SCT1000 is aimed at combating human papillomavirus, marking significant progress in the fight against viral infections that can lead to cancer.
• SCTA01 (For the treatment of SARS COV-2) - In phase 2/3 clinical research trials, this product is part of Sinocelltech’s strategic initiatives to curb the spread and impact of SARS COV-2, reflecting its agile and responsive research capabilities in facing modern health challenges.